drugset
drugset / Trial / NCT05405751

Simplified Model of Linkage and Retention to Care, Using a Mobile Unit and a Same-day Test and Treat Approach Among Excluded Population. (SIMPLIFIED)

NCT05405751 ↗

Phase 4 Completed 101 enrolled Fundacion SEIMC-GESIDA
NaSingle-groupOpen-labelHealth-services research

Summary

Implementation of a model for access and retention of HIV care for vulnerable and excluded population using a mobile screening unit and a strategy of diagnosis and initiation of treatment with Bictegravir (BIC) 50 mg/ Emtricitabine (FTC) 200 mg / Tenofovir Alafenamide (TAF) 25 mg.

Timeline

Start
2022-07-04
Primary completion
2023-12-26
Completion
2024-06-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Bictegravir/Emtricitabine/Tenofovir Alafenamide Unknown 25 mg Oral
Subject Bictegravir/Emtricitabine/Tenofovir Alafenamide Unknown 50 mg Oral
Subject Bictegravir/Emtricitabine/Tenofovir Alafenamide Unknown 200 mg Oral

Indications

HIV infectious disease